The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -5.18 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.34 — no flag raisedOK
- Earnings quality 83/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Oncology Institute, Inc. reports it. History and quarterly detail are in the app.
- Specialty pharmacy$269.2M
- Patient services$229.0M
- FFS revenue$148.5M
- Capitated revenue$80.5M
- Clinical trials & other$4.6M
Leadership changes
From Oncology Institute, Inc.'s own filings, the day they're filed.
- Gabriel Ling · Directors · departureeff. 2025-11-26
- Richard Barasch · Directors · departureeff. 2025-08-12
- Jeremy Castle · Chief Operating Officer · departureeff. 2025-05-30
Latest filings
- 8-K · Company announcement2026-09-02
- 8-K · Company announcement2026-08-21
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-03
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Oncology Institute, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Oncology Institute, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.